Covered recipient · General Payments record
JAMES JONES
General Payments · PY2018–2024
$2,773.10
- Reported across 183 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $254.51 | 15 |
| Education | $16.24 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $91.20 | 5 |
| Grifols USA, LLC | $88.84 | 5 |
| Inari Medical, Inc. | $40.78 | 3 |
| Mylan Specialty L.P. | $18.72 | 1 |
| Insmed, Inc. | $16.24 | 1 |
| GENZYME CORPORATION | $14.97 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $14.97 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139981944 | CMS |
| GlaxoSmithKline, LLC. | $17.61 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116478551 | CMS |
| GlaxoSmithKline, LLC. | $17.58 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116313147 | CMS |
| GlaxoSmithKline, LLC. | $17.61 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116634322 | CMS |
| GlaxoSmithKline, LLC. | $20.83 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116506741 | CMS |
| GlaxoSmithKline, LLC. | $17.57 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116206863 | CMS |
| Grifols USA, LLC | $23.56 | 01/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124716942 | CMS |
| Grifols USA, LLC | $20.24 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124716944 | CMS |
| Grifols USA, LLC | $14.72 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124716946 | CMS |
| Grifols USA, LLC | $16.72 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124716950 | CMS |
| Grifols USA, LLC | $13.60 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124716948 | CMS |
| Inari Medical, Inc. | $14.37 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140115333 | CMS |
| Inari Medical, Inc. | $13.12 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140115337 | CMS |
| Inari Medical, Inc. | $13.29 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140115341 | CMS |
| Insmed, Inc. | $16.24 | 03/19/2024 | Education | Undisputed | 01/23/2026 | 1089573952 | CMS |
| Mylan Specialty L.P. | $18.72 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147304794 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.